Gene therapy for RPE65-related retinal disease

ABSTRACT

Significant discoveries in the etiology and pathogenesis of inherited retinal diseases (IRDs) have been made in the last few decades. Of the large number genes that cause IRDs, bi-allelic mutations in RPE65 lead to Leber Congenital Amaurosis type 2 (LCA 2), and can also result in phenotypes described as severe early childhood onset retinal dystrophy (SECORD) and Retinitis pigmentosa 20 (RP20). Following the publication of the successful Phase-III clinical trials of gene augmentation surgery for RPE65-related IRDs with voretigene neparvovec, the FDA approved the commercial use of this pharmacologic agent in December 2017. In this perspective, ongoing and completed gene therapy trials for RPE65-related dystrophies are reviewed and challenges in patient selection, counseling and informed consent, as well as financial considerations of commercial treatment are discussed.

KEYWORDS:

• RPE65
• gene therapy
• Leber Congenital Amaurosis
• voretigine neparvovec
• clinical trials

Declarations of Interest

Miraldi Utz- Retrophin, Inc-S, Spark Therapeutics-C, Springer-P; Coussa – No financial disclosures; Antaki – No financial disclosures; Traboulsi – Spark Therapeutics –C, Sanofi-S, Springer-P, Oxford University Press-P, Taylor & Francis-P.